SIOUX FALLS, S.D.–(BUSINESS WIRE)–SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high potency, fully-human polyclonal antibodies at scale, today announced that Eddie J. Sullivan, PhD, co-founder, president, CEO, will serve as an expert panelist during BIO Digital 2021.
The panel, “One Health Preparedness and Response: Translating Surveillance of Emerging Zoonotic Diseases into Biotechnology,” will be moderated by Catherine Machalaba, MPH, PhD, senior policy advisor and senior scientist at EcoHealth Alliance. The panel is scheduled on Monday, June 14, 2021, from 11:05 AM to 11:50 AM EDT.
|Event:||BIO Digital 2021|
|Panel Summary:||One Health, or the concept that animal, human, and environmental health are interconnected, has been made readily apparent by the recent COVID-19 pandemic. The World Health Organization estimates that more than 60% of human diseases are zoonotic and that 75% of diseases discovered over the past decade originate in animals. The panelists, who include public health experts and Company leaders, will examine how the biotechnology industry can contribute to solutions to ensure the world is prepared for continuing zoonotic threats to human.|
|Presentation Date:||11:05 AM – 11:50 AM (EDT), Monday, June 14, 2021|
|Link to BIO Partnering:||https://www.bio.org/events/bio-digital/partnering|
Dr. Sullivan commented, “We have spent nearly two decades at SAB developing and optimizing our unique platform that leverages transgenic cows to rapidly produce large quantities of highly potent, fully-human therapeutic polyclonal antibodies targeted at specific diseases. Responding to the COVID-19 pandemic has provided us the opportunity to fully integrate and accelerate scale-up of our drug development, regulatory and production capabilities. We look forward to sharing what we have learned and providing a model for future response with our colleagues committed to applying 21st century biotechnology to combat these ongoing threats to global well-being.”
BIO is the world’s largest advocacy association representing member companies, state biotechnology groups, academic and research institutions, and related organizations across the United States and in 30+ countries. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial, and environmental biotechnology products. For more information on BIO Digital 2021, visit www.bio.org/events/bio-digital.
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc. (SAB) is a clinical-stage biopharmaceutical company advancing a new class of immunotherapies based on its human polyclonal antibodies. Utilizing some of the world’s most advanced genetic engineering and antibody science, SAB has developed transgenic bovine herds that produce fully-human antibodies targeted at fighting specific diseases, including infectious diseases such as COVID-19 and influenza; immune-related disorders including type 1 diabetes, organ transplantation and other autoimmune diseases; as well as complex immune-mediated diseases such as cancer. SAB’s versatile and scalable DiversitAb™ platform is applicable to a wide range of serious human diseases. It rapidly produces natural, specifically-targeted, high-potency, human polyclonal immunotherapies at commercial scale. Development and validation of the platform have benefitted from major support from key US government emerging disease and rapid response programs. The Company is currently advancing multiple clinical programs in a number of indications in addition to collaborations with global pharmaceutical and other partners. For more information visit: www.sabbiotherapeutics.com and follow @SABBantibody on Twitter.